Park Place Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Park Place Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$966	Hold	16	–	–	﹤0.01%	1059
2026 Q1	$930	Hold	16	–	–	﹤0.01%	806
2025 Q4	$717	Hold	16	–	–	﹤0.01%	775
2025 Q3	$642	Hold	16	–	–	﹤0.01%	772
2025 Q2	$513	Hold	16	–	–	﹤0.01%	794
2025 Q1	$537	Buy	+16	New	+$608	﹤0.01%	810
2024 Q4	–	Sell	-18	Closed	-$709	–	883
2024 Q3	$709	Hold	18	–	–	﹤0.01%	840
2024 Q2	$702	Hold	18	–	–	﹤0.01%	845
2024 Q1	$775	Buy	+18	New	+$828	﹤0.01%	888
2023 Q4	–	Sell	-22	Closed	-$752	–	1041
2023 Q3	$752	Hold	22	–	–	﹤0.01%	993
2023 Q2	$847	Buy	+22	New	+$875	﹤0.01%	990

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Park Place Capital's XENE Position: Q2 2026 in Review

Park Place Capital held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 16 shares worth $966. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Park Place Capital first reported a position in XENE in Q2 2023 and has held it in 11 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Park Place Capital held 16 shares of Xenon Pharmaceuticals worth $966 as of Q2 2026.
Park Place Capital left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Park Place Capital's portfolio in Q2 2026, its #1059 holding.
Park Place Capital first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.